GPP
ABEO icon

Great Point Partners’s Abeona Therapeutics ABEO Stock Holding History

Great Point Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-155,717
Closed -$3.97M – 34
2020
Q3 		$3.97M Sell
155,717
-132,803
-46% -$8.37M 0.36% 32
2020
Q2 		$21M Hold
288,520
– – 1.68% 19
2020
Q1 		$15.1M Hold
288,520
– – 1.58% 20
2019
Q4 		$23.6M Buy
288,520
+159,096
+123% +$11.2M 2.05% 15
2019
Q3 		$7.31M Buy
+129,424
New +$9.69M 0.67% 33

Other funds holding ABEO

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Great Point Partners's ABEO Position: Q4 2020 in Review

Great Point Partners sold out of Abeona Therapeutics (ABEO) in Q4 2020, closing a stake of 155,717 shares — an estimated $3.97M sold.

Great Point Partners first reported a position in ABEO in Q3 2019 and held it in 5 quarters. The position peaked at $23.6M in Q4 2019. 73 funds tracked by Wall St. Rank hold ABEO as of Q4 2020.

  • Great Point Partners reported no remaining Abeona Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Great Point Partners sold 155,717 Abeona Therapeutics shares in Q4 2020, an estimated $3.97M.
  • Great Point Partners first reported a position in Abeona Therapeutics in Q3 2019 and held it in 5 quarters.
  • Great Point Partners's Abeona Therapeutics position peaked at $23.6M in Q4 2019.
  • 73 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.